World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
72
Citations
23689
World Ranking
6180
National Ranking
2907

Research.com Recognitions

  • 2016 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

David A. Fruman is affiliated with the University of California, Irvine in the United States. Their research primarily spans the fields of Biochemistry, Genetics, and Molecular Biology, with additional work in Medicine. Within these broad areas, their subfields of study include Molecular Biology, Cancer Research, Genetics, Oncology, and Hematology.

Their scientific contributions address several key topics, such as Cancer, Lipids, and Metabolism; PI3K/AKT/mTOR signaling in cancer; Chronic Lymphocytic Leukemia Research; Cancer, Hypoxia, and Metabolism; Chronic Myeloid Leukemia Treatments; Ubiquitin and proteasome pathways; and Plant biochemistry and biosynthesis.

Among their recent papers are the following:

  • PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer, 2023, Molecular Cancer
  • YAP-mediated mechanotransduction tunes the macrophage inflammatory response, 2020, Science Advances
  • Targeting the Mevalonate Pathway in Cancer, 2021, Trends in Cancer
  • Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth, 2020, Nature Communications
  • An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia, 2020, Blood

Frequent coauthors of David A. Fruman include Roberta Buono, Madhuri Paul, Dennis Juarez, Sharmila Mallya, and Lee-or Herzog.

In terms of publishing venues, the scientist has contributed regularly to Faculty Opinions - Post-Publication Peer Review of the Biomedical Literature, bioRxiv (Cold Spring Harbor Laboratory), Cancer Research, Blood, and Frontiers in Oncology.

David A. Fruman was recognized as a Fellow of the American Association for the Advancement of Science (AAAS) in 2016.

Best Publications

  • The PI3K pathway in human disease

    David A. Fruman;Honyin Chiu;Benjamin D. Hopkins;Shubha Bagrodia

  • PI3K and cancer: lessons, challenges and opportunities

    David A. Fruman;Christian Rommel

  • Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A.

    David A. Fruman;Claude B. Klee;Barbara E. Bierer;Steven J. Burakoff

  • Impaired B Cell Development and Proliferation in Absence of Phosphoinositide 3-Kinase p85α

    David A. Fruman;Scott B. Snapper;Claudine M. Yballe;Laurie Davidson

  • Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase.

    Hwai Wen Chang;Masahiro Aoki;David Fruman;Kurt R. Auger

  • Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals

    Andrew M. Scharenberg;Ousama El-Hillal;David A. Fruman;Laurie O. Beitz

  • Phosphoinositide 3-Kinase: Diverse Roles in Immune Cell Activation

    Jonathan A. Deane;David A. Fruman

  • Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

    Matthew R Janes;Jose J Limon;Lomon So;Jing Chen

  • Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha.

    D.A. Fruman;F. Mauvais-Jarvis;D.A. Pollard;C.M. Yballe

  • Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival.

    Kohjiro Ueki;David A. Fruman;David A. Fruman;Saskia M. Brachmann;Saskia M. Brachmann;Saskia M. Brachmann;Yu-Hua Tseng

  • Immunophilins in protein folding and immunosuppression.

    David A. Fruman;Steven J. Burakoff;Barbara E. Bierer

  • Reduced expression of the murine p85α subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes

    Franck Mauvais-Jarvis;Kohjiro Ueki;David A. Fruman;Michael F. Hirshman

  • Xid-like phenotypes: a B cell signalosome takes shape.

    David A Fruman;Anne B Satterthwaite;Owen N Witte

  • Positive and Negative Roles of p85α and p85β Regulatory Subunits of Phosphoinositide 3-Kinase in Insulin Signaling *

    Kohjiro Ueki;David A. Fruman;Claudine M. Yballe;Mathias Fasshauer

  • Phosphoinositide 3-kinase in immunological systems

    David A Fruman;Lewis C Cantley

  • PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances

    Lomon So;David A. Fruman

  • Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology

    Barbara E. Bierer;Georg Holländer;David Fruman;Steven J. Burakoff

  • Fine tuning the immune response with PI3K

    David A. Fruman;Georges Bismuth

  • Regulation of quiescence in lymphocytes

    Isharat Yusuf;David A. Fruman

  • SYK Is Upstream of Phosphoinositide 3-Kinase in B Cell Receptor Signaling

    Laurie O. Beitz;David A. Fruman;David A. Fruman;Tomohiro Kurosaki;Lewis C. Cantley;Lewis C. Cantley

Frequent Co-Authors

Lewis C. Cantley
Lewis C. Cantley Harvard University
Barbara E. Bierer
Barbara E. Bierer Brigham and Women's Hospital
Steven J. Burakoff
Steven J. Burakoff Icahn School of Medicine at Mount Sinai
Marina Konopleva
Marina Konopleva The University of Texas MD Anderson Cancer Center
Christian Rommel
Christian Rommel Bayer Pharmaceuticals
Davide Ruggero
Davide Ruggero University of California, San Francisco
Thomas E. Lane
Thomas E. Lane University of California, Irvine
C. Ronald Kahn
C. Ronald Kahn Harvard University
Owen N. Witte
Owen N. Witte University of California, Los Angeles
Ze'ev Ronai
Ze'ev Ronai Cedars-Sinai Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing David A. Fruman

Trending Scientists